Key Points
- Director Clay Siegall bought 62,500 shares of Shattuck Labs at $4.00 each, a $250,000 purchase that increased his stake by 24.4% to 318,608 shares.
- Shattuck Labs stock was up 1.2% and opened at $4.18, with the company trading below both its 50-day average of $6.38 and 200-day average of $4.94.
- The biotech company recently beat quarterly EPS estimates by $0.01, and analysts currently rate the stock a Moderate Buy with an average price target of $11.00.
Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) Director Clay Siegall purchased 62,500 shares of the firm's stock in a transaction on Tuesday, June 9th. The shares were acquired at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director owned 318,608 shares in the company, valued at approximately $1,274,432. This trade represents a 24.40% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shattuck Labs Trading Up 1.2%
Shares of Shattuck Labs stock opened at $4.18 on Friday. The business has a 50-day moving average price of $6.38 and a two-hundred day moving average price of $4.94. Shattuck Labs, Inc. has a 1-year low of $0.71 and a 1-year high of $8.33. The company has a market cap of $320.52 million, a P/E ratio of -6.63 and a beta of 1.08.
Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. During the same period last year, the company earned ($0.27) EPS. Equities research analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. Wall Street Zen downgraded Shattuck Labs from a "buy" rating to a "hold" rating in a report on Saturday, May 23rd. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Shattuck Labs in a report on Monday. Citigroup upgraded Shattuck Labs from a "neutral" rating to a "buy" rating and set a $7.00 price target for the company in a report on Friday, June 5th. Cantor Fitzgerald assumed coverage on Shattuck Labs in a report on Monday, April 27th. They set an "overweight" rating for the company. Finally, TD Cowen reiterated a "buy" rating on shares of Shattuck Labs in a report on Friday, March 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $11.00.
Check Out Our Latest Report on STTK
Hedge Funds Weigh In On Shattuck Labs
A number of institutional investors and hedge funds have recently made changes to their positions in STTK. Orbimed Advisors LLC bought a new position in shares of Shattuck Labs during the 3rd quarter worth about $15,072,000. NEXTBio Capital Management LP bought a new position in shares of Shattuck Labs during the 4th quarter worth about $11,497,000. Price T Rowe Associates Inc. MD bought a new position in shares of Shattuck Labs during the 4th quarter worth about $7,031,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Shattuck Labs during the 4th quarter worth about $4,945,000. Finally, Bank of America Corp DE boosted its position in shares of Shattuck Labs by 2,968.2% during the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company's stock worth $2,705,000 after purchasing an additional 1,094,997 shares in the last quarter. Institutional investors own 58.74% of the company's stock.
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.
The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
